Rui Fang1,2, Heng Wang1,2, Yang Li1,2, Yue-Ming Liu1,2, Wen-Bin Wei3,4,5,6,7,8. 1. Beijing Tongren Hospital, Beijing, 100730, China. 2. Capital Medical University, Beijing, 100730, China. 3. Beijing Tongren Hospital, Beijing, 100730, China. weiwenbintr@163.com. 4. Capital Medical University, Beijing, 100730, China. weiwenbintr@163.com. 5. Beijing Tongren Eye Center, Beijing, China. weiwenbintr@163.com. 6. Beijing key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing, China. weiwenbintr@163.com. 7. Beijing Ophthalmology and Visual Sciences Key Lab, Beijing, China. weiwenbintr@163.com. 8. Medical Artificial Intelligence Research and Verification Laboratory of the Ministry of Industry and Information Technology, Beijing, China. weiwenbintr@163.com.
Abstract
BACKGROUND: Tumor regression of uveal melanomas (UMs) after radiotherapy has been reported as a valuable prognostic factor for metastasis and metastatic death. But its effect on prognosis is questionable. The purpose of this study was to summarize the regression features of uveal melanoma after iodine-125 plaque brachytherapy and the relationship with prognosis. METHODS: Adult uveal melanoma patients who only received iodine-125 plaque brachytherapy between December 2009 and March 2018 at the Beijing Tongren Hospital, Capital Medical University were enrolled in this study. The regression rate was calculated as the percent change in tumor height, and each eye was classified for four main regression patterns: Decrease (D), Stable (S), Others (O), and Increase (I), according to the trend of height change. Statistical analysis was performed using one-way ANOVA and chi-square test, univariate and multivariate logistic regression, and Kaplan-Meier analysis. RESULTS: A total of 139 patients was included in the study. The median follow-up was 35 months. Regression patterns status was pattern D in 65 tumors (46.8%), pattern S in 50 tumors (36.0%), pattern O in 6 tumors (4.3%), and pattern I in 18 tumors (12.9%). Reductions of tumor mean height for each follow-up visit were 5.26% (3 months), 10.66% (6 months), 9.37% (12 months), and 14.68% (18 months). A comparison (D vs. S vs. O vs. I) revealed the preoperative height of pattern I was significantly lower than the pattern D, S and O (mean: 7.24 vs. 7.30 vs. 6.77 vs. 5.09 mm, respectively; P = 0.037). LBD (largest basal diameter) was strongly associated with the metastasis (P = 0.03). However, an association between the tumor regression and subsequent melanoma-related metastasis and mortality could not be confirmed (P = 0.66 and P = 0.27, respectively). The tumor regression rate increased with increasing tumor height (P = 0.04) and decreased with increasing of LBD (P = 0.01). CONCLUSION: Our study showed a lack of association between the prognosis and the regression of uveal melanomas following I-125 plaque radiotherapy. The LBD and original height of the tumor have predictive value in tumor regression rate, and LBD was positively associated with metastasis.
BACKGROUND:Tumor regression of uveal melanomas (UMs) after radiotherapy has been reported as a valuable prognostic factor for metastasis and metastatic death. But its effect on prognosis is questionable. The purpose of this study was to summarize the regression features of uveal melanoma after iodine-125 plaque brachytherapy and the relationship with prognosis. METHODS: Adult uveal melanomapatients who only received iodine-125 plaque brachytherapy between December 2009 and March 2018 at the Beijing Tongren Hospital, Capital Medical University were enrolled in this study. The regression rate was calculated as the percent change in tumor height, and each eye was classified for four main regression patterns: Decrease (D), Stable (S), Others (O), and Increase (I), according to the trend of height change. Statistical analysis was performed using one-way ANOVA and chi-square test, univariate and multivariate logistic regression, and Kaplan-Meier analysis. RESULTS: A total of 139 patients was included in the study. The median follow-up was 35 months. Regression patterns status was pattern D in 65 tumors (46.8%), pattern S in 50 tumors (36.0%), pattern O in 6 tumors (4.3%), and pattern I in 18 tumors (12.9%). Reductions of tumor mean height for each follow-up visit were 5.26% (3 months), 10.66% (6 months), 9.37% (12 months), and 14.68% (18 months). A comparison (D vs. S vs. O vs. I) revealed the preoperative height of pattern I was significantly lower than the pattern D, S and O (mean: 7.24 vs. 7.30 vs. 6.77 vs. 5.09 mm, respectively; P = 0.037). LBD (largest basal diameter) was strongly associated with the metastasis (P = 0.03). However, an association between the tumor regression and subsequent melanoma-related metastasis and mortality could not be confirmed (P = 0.66 and P = 0.27, respectively). The tumor regression rate increased with increasing tumor height (P = 0.04) and decreased with increasing of LBD (P = 0.01). CONCLUSION: Our study showed a lack of association between the prognosis and the regression of uveal melanomas following I-125 plaque radiotherapy. The LBD and original height of the tumor have predictive value in tumor regression rate, and LBD was positively associated with metastasis.
Authors: Daniel Lorenzo; Josep Maria Piulats; María Ochoa; Luis Arias; Cristina Gutiérrez; Jaume Català; Estefanía Cobos; Pere Garcia-Bru; Bruno Dias; Noel Padrón-Pérez; Josep Maria Caminal Journal: Jpn J Ophthalmol Date: 2019-02-22 Impact factor: 2.447
Authors: Omkar S Marathe; Jeffrey Wu; Steve P Lee; Fei Yu; Barry L Burgess; Min Leu; Bradley R Straatsma; Tara A McCannel Journal: Int J Radiat Oncol Biol Phys Date: 2010-10-06 Impact factor: 7.038
Authors: Patrick J T Chiam; Sarah E Coupland; Helen Kalirai; Carl Groenewald; Heinrich Heimann; Bertil E Damato Journal: Br J Ophthalmol Date: 2014-02-11 Impact factor: 4.638
Authors: Jingting Luo; Yuning Chen; Yuhang Yang; Kai Zhang; Yueming Liu; Hanqing Zhao; Li Dong; Jie Xu; Yang Li; Wenbin Wei Journal: Front Med (Lausanne) Date: 2022-01-21